

# MEDICARE REIMBURSEMENT RATES

	<b>SYNVISC® (hylan G-F 20)</b>	<b>Synvisc-One® (hylan G-F 20)</b>
<b>Number of syringes</b>	3 (16 mg/syringe)	1 (48 mg/syringe)
<b>Medicare allowable* ASP +6.0%</b> (per course of treatment)		
<b>Medicare allowable* ASP +6.0%</b> (per syringe)		
<b>Medicare allowable* ASP +6.0%</b> (per 1 mg)		
<b>Medicare allowable† ASP +4.3%</b> (per course of treatment)		
<b>Medicare allowable† ASP +4.3%</b> (per syringe)		
<b>Medicare allowable† ASP +4.3%</b> (per 1 mg)		
<b>HCPCS code</b>	J7325	J7325

\*Reimbursement information obtained from CMS Web site at [www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html). Accessed on

†As of March 1, 2013, Medicare is subject to the sequester in the form of provider payment cuts of up to 2%.

This information is provided as an estimate on what a provider may expect as reimbursement.

Providers are responsible for the selection of appropriate codes depending on clinical diagnosis and this information is not intended to substitute for the physician's independent diagnosis. Providers retain sole responsibility for determining reimbursement and for ensuring the accuracy of their claims submission. Sanofi cannot be responsible for failure of a provider to obtain reimbursement.

**SANOFI BIOSURGERY** 

Manufactured by  
Genzyme, a Sanofi Company  
55 Cambridge Parkway  
Cambridge, MA 02142  
1-888-3-SYNVISC

SYNVISC, Synvisc-One and Genzyme are registered trademarks of Genzyme, a Sanofi Company.

© SANOFI US. All rights reserved. Printed in the USA. SAUS.HYL.17.12.9700